Rescue Analysis of Utrophin & NMJ Support by Syntrophin
Project Number5R01NS044211-02
Contact PI/Project LeaderSEALOCK, ROBERT W
Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
DESCRIPTION (provided by applicant): The syntrophins are a family of peripheral membrane adapter proteins that function in association with dystrophin, utrophin, and the dystrobrevins, all of which are proteins of the surface membrane of skeletal muscle and implicated in the important human disease, Duchenne muscular dystrophy (DMD). Alpha-syntrophin is the major syntrophin in muscle. In the alpha-syntrophin knockout mouse, the postsynaptic membrane at the neuromuscular junction shows major biochemical and morphological defects including low amounts of acetylcholine receptors and acetylcholinesterase, a complete absence of utrophin, immature appearing contacts, junctional folds that are disorganized and few in number, and altered distribution of AChR. Thus, there is a utrophin and NMJ support function of alpha-syntrophin. The first two aims of the project are to intended to extend current understanding that the other syntrophins of muscle (beta1, beta2, and probably gamma2) are not redundant with alpha-syntrophin. They are: 1) Test the hypothesis that transgenically expressed beta 1-syntrophin will restore utrophin to adult alpha-syntrophin 4- junctions but will not rescue other, or all other, aspects of the phenotype. 2) Test the hypothesis that transgenically expressed beta 2-syntrophin will restore no aspects of the alpha-syntrophin -/- phenotype. The results will provide a solid framework for molecular analysis of the mechanisms of the support function. Aim 3) Identify the critical functional domains of the alpha-syntrophin molecule by transgenic expression in alpha-syntrophin -/- mice of a) chimeric proteins containing domains of beta substituted into alpha-syntrophin (or the converse, alpha into beta) and/or b) alpha-syntrophin specifically mutagenized at selected sites. The results will identify domains and implicate syntrophin-dependent pathways. Aim 4) Determine whether low levels of utrophin mRNA, inability of the membrane to accept utrophin incorporation, or both contribute to the lack of utrophin at alpha-syntrophin -/- NMJs. If applicable, use these tools to analyze the transgenic mice. 5) Seek to identify determinants in the AChR accumulation pathway-- AChR mRNA levels, total AChR expression, cell surface AChR expression, AChR clustering response to agrin, stability of agrin-induced clusters--that may contribute to the low AChR content of alpha-syntrophin 4- NMJs. If applicable, use the understanding so generated to analyze the transgenic mice.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
608195277
UEI
D3LHU66KBLD5
Project Start Date
30-September-2003
Project End Date
30-June-2007
Budget Start Date
01-July-2004
Budget End Date
30-June-2005
Project Funding Information for 2004
Total Funding
$303,863
Direct Costs
$208,125
Indirect Costs
$95,738
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Neurological Disorders and Stroke
$303,863
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS044211-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS044211-02
Patents
No Patents information available for 5R01NS044211-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS044211-02
Clinical Studies
No Clinical Studies information available for 5R01NS044211-02
News and More
Related News Releases
No news release information available for 5R01NS044211-02
History
No Historical information available for 5R01NS044211-02
Similar Projects
No Similar Projects information available for 5R01NS044211-02